Raloxifene hydrochloride as hepatitis C treatment

Autores: Motola Kuba Miguel, Méndez Sánchez Nahum


COMMENT Chronic hepatitis C infections appears to progress more rapidly in men than in women, and cirrhosis is predominately a disease of men and postmenopausal women. Several studies have shown that estrogens specifically Estradiol is a potent endogenous antioxidant that may slow fibrosis progression. One study revealed that menopause appears to be associated with accelerated liver fibrosis progression in HCV-infected women, an effect that may be prevented with hormone replacement therapy, even pregnancy may have a beneficial impact on the longterm progression of liver fibrosis. Another study revealed that non alcoholic liver disease is more prevalent in postmenopausal than premenopausal women. Raloxifene is an oral selective estrogen receptor modulator that directly protect hepatocytes and control liver fibrosis.

Palabras clave:

2013-07-09   |   242 visitas   |   3 valoraciones

Vol. 12 Núm.1. Enero-Febrero 2013 Pags. 164-165 Ann Hepatol 2013; 12(1)